Apellis Pharmaceuticals

$27.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.20 (-4.26%) Today
+$0.50 (1.85%) As of 4:03 PM EDT after-hours

Why Robinhood?

You can buy or sell APLS and other stocks, options, ETFs, and crypto commission-free!

About APLS

Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. Read More It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Crestwood, KY.

Employees
87
Headquarters
Crestwood, Kentucky
Founded
2009
Market Cap
1.72B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
827.15K
High Today
$28.59
Low Today
$26.75
Open Price
$28.20
Volume
874.96K
52 Week High
$33.18
52 Week Low
$11.45

Collections

APLS Earnings

-$1.12
-$0.89
-$0.66
-$0.43
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 13, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.